News Image

Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Provided By GlobeNewswire

Last update: Sep 13, 2024

-  Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy dose escalation

Read more at globenewswire.com

PRELUDE THERAPEUTICS INC

NASDAQ:PRLD (7/31/2025, 8:00:02 PM)

After market: 0.78 +0 (+0.01%)

0.7799

-0.04 (-4.88%)



Find more stocks in the Stock Screener

Follow ChartMill for more